FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523688719> ?p ?o ?g. }

• W2523688719 endingPage "5474" @default.
• W2523688719 startingPage "5474" @default.
• W2523688719 abstract "Abstract Introduction The management of heavily pre-treated patients with relapsed ATLL is challenging. These patients display chemo-refractory disease with limited therapeutic options. The Kyowa Hakko Kirin protocol 0761-009 is a randomized controlled trial of anti-CCR4 monoclonal antibody therapy (mogamulizumab) compared with physician choice of salvage chemotherapy in relapsed ATLL. ATLL arises in HTLV-1 infected patients with high pre-morbid HTLV-1 proviral loads (>4–10 HTLV-1 DNA copies/ml)1. Methods Three patients, female, age 38 - 72 years and of Afro Caribbean origin, with relapsed chronic ATLL, have been recruited to 0761-009 in London. All patients had received two or more lines of therapy: #1 zidovudine (ZDV)/Interferon-a (IFN), anti-CD25/bortezomib; #2 ZDV/INF, anti-CD25/bortezomib, etoposide, Gemcitabine/Oxaloplatin; #3 sodium valproate, ZDV/IFN, etoposide. Lymphocyte counts at study entry were 7.8 - 33.5 x 109/L with high HTLV-1 proviral loads (range 25.4 - 122.4 HTLV-1 DNA copies/100 PBMC). Anti-CCR4 mAb was administered at a dose of 1mg/kg over 1 hour, weekly for 4 weeks and every 2 weeks thereafter. Data were censored 17/06/2014. Results All three patients achieved complete hematological remission (CR) after 1 – 2 infusions. Patient #1 remains on treatment and in CR day 397. Patient #2 received 3 treatment cycles with normalization of lymphocyte count and complete resolution of extensive cutaneous lesions (baseline SWAT= 93.6) but treatment was discontinued after 3 cycles due to, now resolved, drug toxicity. Patient #3 remains on treatment and in CR at day 139. In each case HTLV proviral load fell to 0.02% < 0.7% and have remained <1% for the duration of therapy. Conclusions Although a small case series these data illustrate the efficacy of anti-CCR4 mAb in ATLL, particularly in the chronic form, despite prior treatment failure and support the data observed in the Japanese cohort where CR was achieved in patients with blood compartmental disease, particularly chronic ATLL2. However, the extent of reduction in HTLV-1 proviral load with anti-CCR4 was not observed previously in these patients (or others who achieved CR with zidovudine/interferon the first line treatment of chronic ATLL). The reduction in HTLV-1 proviral burden to <1% suggests not only clearance of circulating HTLV-1 infected malignant clones but additional depletion of HTLV-1 infected non-malignant clones. This will be confirmed by unique integration site analysis. Reference List (1) Hodson A, Laydon D, Bain BJ, Fields P, Taylor GP. Pre-morbid HTLV-1 proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive ATLL. Haematologica2013; 98(3):385-388. (2) Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30(8):837-842. Disclosures No relevant conflicts of interest to declare." @default.
• W2523688719 created "2016-09-30" @default.
• W2523688719 creator A5005039311 @default.
• W2523688719 creator A5034786612 @default.
• W2523688719 creator A5062600050 @default.
• W2523688719 creator A5070164229 @default.
• W2523688719 creator A5083751425 @default.
• W2523688719 creator A5084702053 @default.
• W2523688719 creator A5087466379 @default.
• W2523688719 creator A5091115060 @default.
• W2523688719 date "2014-12-06" @default.
• W2523688719 modified "2023-09-27" @default.
• W2523688719 title "Achievement of Complete Hematological Remission and Reversal of High HTLV-1 Viral Loads with Anti CCR-4 Monoclonal Antibody Administration in Afro Caribbean Patients with Relapsed Chronic Adult T Cell Leukaemia (ATLL)" @default.
• W2523688719 doi "https://doi.org/10.1182/blood.v124.21.5474.5474" @default.
• W2523688719 hasPublicationYear "2014" @default.
• W2523688719 type Work @default.
• W2523688719 sameAs 2523688719 @default.
• W2523688719 citedByCount "1" @default.
• W2523688719 countsByYear W25236887192023 @default.
• W2523688719 crossrefType "journal-article" @default.
• W2523688719 hasAuthorship W2523688719A5005039311 @default.
• W2523688719 hasAuthorship W2523688719A5034786612 @default.
• W2523688719 hasAuthorship W2523688719A5062600050 @default.
• W2523688719 hasAuthorship W2523688719A5070164229 @default.
• W2523688719 hasAuthorship W2523688719A5083751425 @default.
• W2523688719 hasAuthorship W2523688719A5084702053 @default.
• W2523688719 hasAuthorship W2523688719A5087466379 @default.
• W2523688719 hasAuthorship W2523688719A5091115060 @default.
• W2523688719 hasConcept C126322002 @default.
• W2523688719 hasConcept C203014093 @default.
• W2523688719 hasConcept C2776694085 @default.
• W2523688719 hasConcept C2776755627 @default.
• W2523688719 hasConcept C2777761686 @default.
• W2523688719 hasConcept C2777990475 @default.
• W2523688719 hasConcept C2778119113 @default.
• W2523688719 hasConcept C2779429289 @default.
• W2523688719 hasConcept C2780775027 @default.
• W2523688719 hasConcept C2781413609 @default.
• W2523688719 hasConcept C71924100 @default.
• W2523688719 hasConcept C90924648 @default.
• W2523688719 hasConceptScore W2523688719C126322002 @default.
• W2523688719 hasConceptScore W2523688719C203014093 @default.
• W2523688719 hasConceptScore W2523688719C2776694085 @default.
• W2523688719 hasConceptScore W2523688719C2776755627 @default.
• W2523688719 hasConceptScore W2523688719C2777761686 @default.
• W2523688719 hasConceptScore W2523688719C2777990475 @default.
• W2523688719 hasConceptScore W2523688719C2778119113 @default.
• W2523688719 hasConceptScore W2523688719C2779429289 @default.
• W2523688719 hasConceptScore W2523688719C2780775027 @default.
• W2523688719 hasConceptScore W2523688719C2781413609 @default.
• W2523688719 hasConceptScore W2523688719C71924100 @default.
• W2523688719 hasConceptScore W2523688719C90924648 @default.
• W2523688719 hasIssue "21" @default.
• W2523688719 hasLocation W25236887191 @default.
• W2523688719 hasOpenAccess W2523688719 @default.
• W2523688719 hasPrimaryLocation W25236887191 @default.
• W2523688719 hasRelatedWork W1568769885 @default.
• W2523688719 hasRelatedWork W1987935529 @default.
• W2523688719 hasRelatedWork W2056602708 @default.
• W2523688719 hasRelatedWork W2077242620 @default.
• W2523688719 hasRelatedWork W2091361215 @default.
• W2523688719 hasRelatedWork W2121694206 @default.
• W2523688719 hasRelatedWork W2346904363 @default.
• W2523688719 hasRelatedWork W2370952297 @default.
• W2523688719 hasRelatedWork W2403217642 @default.
• W2523688719 hasRelatedWork W3094869008 @default.
• W2523688719 hasVolume "124" @default.
• W2523688719 isParatext "false" @default.
• W2523688719 isRetracted "false" @default.
• W2523688719 magId "2523688719" @default.
• W2523688719 workType "article" @default.